News

In conclusion, intravesical disitamab vedotin appears to be safe and well-tolerated in HER2-expressing high-risk NMIBC, with promising early signs of efficacy. No maximum tolerated dose was reached, ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.